Gene-editing technology allows scientists to measure alpha-synuclein levels

Researchers from the University of Central Florida (FL, USA) are using CRISPR gene-editing technology to develop a novel screening tool for Parkinson’s disease. Their findings demonstrate how the research team could “light up” and monitor the brain protein alpha-synuclein, which has been associated with this neurodegenerative disease. The study was published in Scientific Reports and could lead to new therapeutic strategies for Parkinson’s. Levi Adams (University of Central Florida), one of the study investigators, commented: “Alpha-synuclein is a protein that is normally found in the brain. We all have it. But for some reason, when you have Parkinson's the levels...